These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33236071)

  • 41. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.
    Keeney M; Wood BL; Hedley BD; DiGiuseppe JA; Stetler-Stevenson M; Paietta E; Lozanski G; Seegmiller AC; Greig BW; Shaver AC; Mukundan L; Higley HR; Sigman CC; Kelloff G; Jessup JM; Borowitz MJ
    Cytometry B Clin Cytom; 2018 Mar; 94(2):239-249. PubMed ID: 28475275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
    Luria D; Rosenthal E; Steinberg D; Kodman Y; Safanaiev M; Amariglio N; Avigad S; Stark B; Izraeli S;
    Cytometry B Clin Cytom; 2010 Nov; 78(6):365-71. PubMed ID: 20632326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
    Shaver AC; Seegmiller AC
    Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.
    Zhou T; Karrs J; Ho T; Doverte A; Kochenderfer JN; Shah NN; Yuan CM; Wang HW
    Cytometry B Clin Cytom; 2023 Jul; 104(4):294-303. PubMed ID: 36433814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry.
    Kallakury BV; Hartmann DP; Cossman J; Gootenberg JE; Bagg A
    Am J Clin Pathol; 1999 Jun; 111(6):759-66. PubMed ID: 10361511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Lebecque B; Besombes J; Dannus LT; De Antonio M; Cacheux V; Grèze V; Montagnon V; Veronese L; Tchirkov A; Tournilhac O; Berger MG; Veyrat-Masson R
    Br J Haematol; 2024 May; 204(5):1872-1881. PubMed ID: 38432068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
    Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
    Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
    DiGiuseppe JA; Tadmor MD; Pe'er D
    Cytometry B Clin Cytom; 2015; 88(5):294-304. PubMed ID: 25974871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2021 Sep; 41(3):485-495. PubMed ID: 34304777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).
    Nagler A; Condiotti R; Rabinowitz R; Schlesinger M; Nguyen M; Terstappen LW
    Med Oncol; 1999 Sep; 16(3):177-87. PubMed ID: 10523797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
    Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
    Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiparametric flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia of early B-cell phenotype.
    Mlcáková A; Babusíková O
    Neoplasma; 2003; 50(6):416-21. PubMed ID: 14689062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal residual disease monitoring cannot fully replace bone marrow morphology in assessing disease status in pediatric acute lymphoblastic leukemia.
    Rathe M; Preiss B; Marquart HV; Schmiegelow K; Wehner PS
    APMIS; 2020 May; 128(5):414-419. PubMed ID: 32108963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.